The current Hims & Hers Weight Loss offering is tracking to eclipse $100M in revenue by the end of 2025 1 , as previously discussed, growing faster than any speciality in the companys history
In the phase 2 trial, participants started at 4 mg without escalation experienced significantly more adverse events than those who began at 2 mg
However, semaglutide and tirzepatide will likely remain appropriate first line options for patients with less severe obesity or those who prefer established medications with longer safety track records
After the shortage changes, patient-specific 503A compounding is generally discussed under a narrower legal and regulatory framework
Healthy Fats Are Back Whole-food fats from eggs, seafood, nuts, seeds, olives, avocados, butter, beef tallow and olive oil are now recognized as essential not harmful
Most compounding pharmacies specify refrigerated storage with limited room temperature exposure